A Phase 3 interventional study of Esomeprazole IV and Omeprazole IV in Gastrointestinal Hemorrhage, sponsored by AstraZeneca. Completed at 7 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-03-12.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Gastrointestinal Hemorrhage with a site in China — 8 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · China.
Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 3, and was the 4th registered.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
Browse Gastrointestinal Hemorrhage studies →8 of the 40 studies in Gastrointestinal Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Chinese University of Hong Kong · Sites in China
Ages 18+
Xingshun Qi · Sites in China, United States, Brazil and 5 more countries
Ages 18+
Chinese University of Hong Kong · Sites in China, Hong Kong, Thailand
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 440 is above the median of 98 across 210 interventional studies indexed under Gastrointestinal Hemorrhage.
Median enrollment 101 across the 33 interventional studies, 476 across the 7 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Gastrointestinal Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastrointestinal Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129031Phase 3Xijing HospitalOptimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock | 2027-06-30 |
| NCT06776029Sixth Affiliated Hospital, Sun Yat-sen UniversityFecal Microbiota Transplantation for Radiation-Induced Proctopathy | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of Esomeprazole and Omeprazole intravenous every 12 hours for 5 days in subjects with acute non-variceal upper gastrointestinal bleeding
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluate the efficacy by assessment of proportion of subjects who present with no clinically significant bleeding after 5 days treatment
Proportion of subjects who present with no clinically significant upper GI bleeding after 72-hour treatment
Time to absence of clinically significant upper GI bleeding
The record gives a start of Aug 2006 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Esomeprazole · Omeprazole